Newspaper Publication for Unaudited Standalone & Consolidated Financial Results for Quarter ended 30th June, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has published its Q1 FY26 (quarter ended 30 June 2025) unaudited financial results in newspapers (Financial Express and Mumbai Lakshadweep) as required by SEBI listing rules. On a standalone basis, total income from operations rose to about ₹80.80 lakh versus ₹46.13 lakh in the same quarter last year, and net profit after tax nearly doubled to ₹69.22 lakh (from ₹34.68 lakh). Standalone EPS stood at ₹0.50 compared with ₹0.27 in Q1 FY25. On a consolidated basis, net profit after tax was around ₹111.74 lakh with EPS of ₹0.66. The results were reviewed by the audit committee on 28 July 2025, approved by the Board on 29 July 2025, and received an unqualified limited review report from the statutory auditor. The consolidated results include its wholly owned subsidiary Eiko Scientific Solutions LLP, subsidiary Eikavivity Logistics Pvt Ltd, and associate Reflux Pharmaceuticals Pvt Ltd.
The sharp year-on-year rise in both standalone revenue and profit suggests improving business momentum, which is mildly positive for shareholders. As this is only a newspaper publication of already-approved quarterly results, no direct share-price reaction is expected, though investors can review the full numbers on the BSE and company websites.